Skip to main content
2025 AANS Annual Scientific Meeting Main banner
Back

    Nima Etminan, MD

    Chairman
    Dept. of Neurosurgery, Medical Faculty Mannheim

    Nima Etminan is Chairman & Professor in the Department of Neurosurgery at the University Hospital Mannheim, University of Heidelberg, Germany.

    He has distinct clinical expertise in microsurgical management of cerebrovascular diseases, especially for aneurysms, arteriovenous malformations and steno-occlusive vessel disease.

    Scientifically, he is an expert on unruptured intracranial aneurysms and aneurysmal subarachnoid hemorrhage (SAH). His translational research on aneurysms and subarachnoid hemorrage aims at) unraveling their pathogenesis and the role of modifialbe risk factors, b) developing novel biomarkers for aneurysm rupture and c) to explore new treatment strategies: He is the co-PI of the ‘Prospective Randomized Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms’ (PROTECT-U). This first-ever phase III trial in the setting of unruptured intracranial aneurysms was initiated to provide low-risk medical treatment strategies for those patients that do not immediately require preventive aneurysm repair. Additionally, he has been the Co-PI in 2 phase II trials and 1 phase III trial on prevention of delayed cerebral ischemia after subarachnoid hemorrhage.

    Aside from his translational research, he has a distinct insterest in harmonization the management of unruptured aneurysm management. He successfully co-chaired the European Stroke Organisation (ESO) guideline committee on Management of Unruptured Intracranial Aneurysms. He is currently Co-Chair of the Guidelines for the German Neurology Society for Management of Unruptured Intracranial Aneurysms and Chair the European Stroke Organisation (ESO) guideline working group on Management of aneurysmal subarachnoid haemorrhage.

    He has authored or co-authored over 120 manuscripts, most of them in the field of unruptured intracranial aneurysms or aneurysmal SAH, in reputable journals including Lancet Neurology, JAMA Neurology, Nature Review Neurology, Neurology, and Stroke. He is/has been a member of the Editorial Boards in Stroke, Translational Stroke Research and Cerebrovascular Diseases.

    His ultimately clinical and scientific goal is to reduce the burden of patients with intracranial aneurysms by providing them scientifically proven management guidance and excellent treatment.

    Disclosure(s): No financial relationships to disclose

    Presentation(s):